Kurumun Atıf Alan Makalesi
Atıf Alan Yayın
Leptin influences cellular differentiation and progression in prostate cancer
Scopus
Toplam 136 atıf DOI
Purpose: Several studies have shown a positive association of dietary fat with prostate cancer. Leptin, a peptide hormone that has a role in the regulation of body weight, currently serves as a more accurate biomarker for total body fat. We designed a study to determine whether leptin influences cellular differentiation and the progression of prostate cancer. Materials and Methods: In this study we investigated serum leptin in 21 patients with prostate cancer, 50 with benign prostatic obstruction and 50 healthy individuals matched for sex, body mass index and age. Patients with cancer were stratified into 2 groups by the disease spread, including groups 1 - organ confined and 2 - advanced disease, and into 3 groups by the differentiation degree, including groups 3 - Gleason sum 2 to 4 or well differentiated, 4 - Gleason sum 5 to 7 or moderately differentiated and 5 - Gleason sum 8 to 10 or poorly differentiated. Results: We noted significant differences in serum leptin in the cancer versus control and cancer versus benign prostatic obstruction groups. In addition, in the prostate cancer group serum leptin correlated with prostate specific antigen and biopsy Gleason score. We also observed significant differences in serum leptin in groups 1 versus 2, 3 versus 5 and 4 versus 5. Conclusion: Leptin may have roles in the development of prostate cancer through testosterone and factors related to obesity. It influences cellular differentiation and the progression of prostate cancer.
Atıf Kaynağı
Atıf Yapan Yayın
Prostate cancer and adiponectin
Scopus
Havuzumuzda 261 atıf almış
Objectives. To search for any relation between plasma adiponectin levels and the cellular differentiation or progression of prostate cancer (PCa). PCa is becoming an increasingly important public health problem, particularly for those countries with a trend toward an aging population. Because insulin resistance in the setting of obesity is associated with the development of PCa, we hypothesized that decreased adiponectin levels might underlie the association between PCa and obesity/insulin resistance. Methods. In this study, we investigated plasma adiponectin levels in 30 patients with PCa, 41 subjects with benign prostatic obstruction, and 36 healthy individuals. The body mass index and age of the groups were similar. Patients with PCa were stratified into two groups according to the spread of the disease as organ-confined and advanced disease and into three groups according to grade (low, intermediate, and high grade determined by a Gleason sum of less than 5, between 5 and 7, and more than 7, respectively). Results. Plasma adiponectin levels were significantly lower in the PCa group than in the benign prostatic obstruction group or controls (P <0.001 for both). Additionally, the plasma adiponectin levels were significantly lower in the advanced disease group than in the organ-confined PCa group (P = 0.012). Significant negative associations were found between plasma adiponectin levels and prostate-specific antigen levels or biopsy Gleason scores in the PCa group. The plasma adiponectin levels of those with high-grade PCa were also significantly lower than those for both the low-grade and intermediate-grade groups (P <0.001 for both). Conclusions. The results of the present study imply that plasma adiponectin levels are not only lower in patients with PCa but are also negatively associated with the histologic grade and disease stage. Future prospective studies are recommended to establish any causal relation between PCa and plasma adiponectin levels. © 2005 Elsevier Inc.
Atıf Yapan Makale Bilgileri
Kurumlar (1)
Gülhane Eğitim ve Araştırma Hastanesi
Ankara, Turkey